Adult Dosing
Paroxysmal/persistent atrial fibrillation/atrial flutter
- 400 mg PO bid with morning and evening meals
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Therapy is not recommended in patients with HF with recent decompensation requiring hospitalization or NYHA Class IV symptoms
- Monitor cardiac rhythm no less than every 3 months. Cardiovert patients or discontinue the therapy if patients are in A-fib
- Therapy may increase risk of stroke in patients with permanent atrial fibrillation. Only initiate dronedarone in patients who are receiving appropriate antithrombotic therapy
- Suspend or discontinue the drug on worsening or occurrence of heart failure
- Hepatocellular liver injury/failure requiring transplant has been reported in postmarketing settings in patients treated with dronedarone. Discontinue the therapy if hepatic injury is suspected and evaluate serum enzymes, AST, ALT, alkaline phosphatase, and serum bilirubin. Obtain periodic hepatic serum enzymes, particularly during first 6 months of therapy. Do not resume therapy without another explanation for observed liver injury
- Interstitial lung disease including pneumonitis and pulmonary fibrosis may occur in patients treated with dronedarone. Evaluate onset of dyspnea or non-productive cough occurring due to pulmonary toxicity. Discontinue the treatment if pulmonary toxicity is confirmed
- Concomitant administration of potassium-depleting diuretics may cause hypokalemia or hypomagnesemia, so monitor and maintain the potassium levels before and during drug administration
- Discontinue if QTc Bazett
500ms - Prominent increase in serum creatinine, prerenal azotemia and acute renal failure, often in the setting of heart failure or hypovolemia have been reported; typically reversible when drug discontinued, hence monitor renal function periodically. Serum creatinine levels raises by 0.1 mg/dL rapidly; reaches a plateau after 7 days; reversible after discontinuation
- Effective contraception is advised in women with childbearing potential
- Avoid use in pregnancy and nursing mothers
Caution: Use cautiously in
Supplemental Patient Information
- Patients are advised to consult physician on occurrence of sign and symptoms of heart failure
Pregnancy Category:X
Breastfeeding: Possibly unsafe; unknown whether excreted in breast milk; excreted in rat milk; minor reduced body-weight gain was observed in the offspring on maternal administration of drug in clinical trials; manufacturer has advised either to discontinue the nursing or drug depending on the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Multaq 400 MG TABS [Bottle] (SANOFI-AVENTIS U.S.)
60 mg = $276
180 mg = $779.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
